- Regular Price
- MRP 19.99
- Sale Price
- MRP 19.99
- Regular Price
- MRP 19.99
- Unit Price
- per
Table of contents
Chronic inflammation is a condition that usually doesn't show up as an observable symptom, such as a swollen ankle or a sore throat. It takes over months and years to develop, and it is now recognized as a key contributor to cardiovascular disease, type 2 diabetes, neurodegenerative disorders, cancer, and obesity (Nakadate et al., 2025). Atherosclerosis, which is a common cause of many other cardiovascular diseases, is itself classified as an advanced chronic inflammatory disease (Dabravolski et al., 2023). This interconnection between chronic inflammation and disease occurrence lets the researchers focus on studying anti-inflammatory essential oils and analyzing if the claims made for aromatherapy are correct or need to be re-evaluated. This article analyzes the evidence for aromatherapy and chronic inflammation at three levels, namely molecular mechanism, preclinical models, and human trials, and states where each level supports a conclusion and where it does not.
Acute inflammation is the body's protective response to tissue damage or infection, rather than inflammation, and it resolves once healing is complete. When the resolution is inadequate, or the stimulus persists, the response progresses into chronic inflammation, which is linked to the development of cancer and neurodegenerative and autoimmune diseases (de Lavor et al., 2018). The causes of chronic inflammation are therefore best understood as persistent or unresolved triggers that keep the immune response or inflammation active after it should have shut down. Oxidative stress reinforces this process of inflammation, because inflammatory signaling and oxidative damage feed each other (de Lavor et al., 2018).
At the molecular level, the process is driven by different immuno-signaling pathways. The nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways regulate the production of pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), and they also drive the enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) (de Lavor et al., 2018). Clinically, these processes produce the signs of chronic inflammation that clinicians look for, including persistent fatigue, low-grade pain, joint stiffness, and elevated blood markers such as C-reactive protein, IL-6, and TNF-α. These chronic inflammation symptoms are often non-specific, which is why the condition is frequently recognized only after a related disease has developed. A chronic inflammation diet that is rich in antioxidants and low in heavily processed foods addresses the baseline inflammatory load, and it is the foundation on which any complementary approach, including aromatherapy, should be considered.
Target pathways of inflammation |
Role in chronic inflammation |
Documented essential oil activity on inflammation |
Evidence type |
Source |
NF-κB and MAPK signaling |
Regulate transcription of pro-inflammatory cytokines |
Hibiscus sabdariffa and Citrus aurantium oils inhibited both pathways and reduced expression of transcription factors for IL-1β, IL-6, and TNF-α; eucalyptus oils reduced the lipopolysaccharide-induced response through MAPK and NF-κB |
Macrophage cell assays |
de Lavor et al., 2018; Ho et al., 2020 |
COX-2 and iNOS |
Produce prostaglandins and nitric oxide that sustain inflammation over swelling, pain, and tissue damage |
Reduced expression of both enzymes by the same oils interfering with inflammation |
Macrophage cell assays |
de Lavor et al., 2018 |
Reactive oxygen and nitrogen species |
Oxidative stress and inflammation reinforce one another. |
Seven oils, including Citrus reticulata and Citrus aurantium, reduced ROS and RNS in macrophages; ginger and black pepper oils scavenged superoxide, DPPH, and hydroxyl radicals and inhibited lipid peroxidation. |
Cell assays and animal studies |
de Lavor et al., 2018 |
PPARγ |
Nuclear receptor with anti-inflammatory activity |
1,8-cineole (eucalyptol) was identified as a PPARγ agonist that alleviated colon inflammation |
Docking and colon inflammation models |
Venkataraman et al., 2023 |
Topical delivery |
Determines whether an active compound reaches tissues undergoing inflammation |
Bergamot oil co-loaded with ammonium glycyrrhizinate in nanocarriers showed in vivo topical anti-inflammatory efficacy, and the authors note that the poor physicochemical properties of the unformulated compounds compromise topical application. |
In vivo preclinical study |
Cristiano et al., 2022 |
Metabolic-inflammatory crosstalk |
Links insulin resistance, oxidative damage, and gut microbiota to inflammatory load |
Essential oil effects on insulin sensitivity, oxidative damage, and gut microbiota regulation have been reviewed across metabolic diseases |
Reviewed literature |
Li et al., 2025 |
Three observations are noted in this table.
The primary review selected 30 preclinical articles that tested essential oils and their compounds in vitro and in vivo models of chronic inflammation (de Lavor et al., 2018).
Evidence tier |
What it can show in terms of inflammation control |
What it cannot show in terms of inflammation control |
Examples cited in this article |
In vitro (cell culture) |
Pathway inhibition and cytokine reduction at defined concentrations |
Absorption, metabolism, tissue concentration, or effects beyond a single cell type |
Macrophage assays (de Lavor et al., 2018; Ho et al., 2020) |
Animal models |
Effects on edema, joint, or colon pathology in a whole organism |
Dose and route equivalence in humans; species differences |
Osteoarthritis model (Mohammadifar et al., 2021); colon inflammation (Venkataraman et al., 2023); topical model (Cristiano et al., 2022) |
Human randomized trials |
Change in symptoms in patients |
Mechanism, or disease modification, unless it is measured |
Meta-analysis of eight trials (Bakó et al., 2023); basil oil trial (Askari et al., 2024) |
The human tier deserves closer reading because it is the only tier that speaks to patients. A meta-analysis of eight randomized controlled trials found that topical essential oils reduced pain intensity compared with placebo in musculoskeletal disorders, including knee and hand osteoarthritis and rheumatoid arthritis. The mean difference in pain intensity was −0.87 immediately after application (p = 0.014), −0.58 at one week (p = 0.077), and −0.52 at four weeks (p = 0.049), and stiffness improved by a mean difference of −0.77 compared with no intervention (p = 0.061) (Bakó et al., 2023). Analytically, these figures show a consistent direction of effect and a statistically significant result at the first and last time points, but they also show that the one-week and stiffness results did not reach the conventional 0.05 threshold. The authors conclude that topical essential oils are beneficial as an add-on treatment for pain and stiffness (Bakó et al., 2023), and that conclusion is appropriately modest.
A second point concerns the outcome that was measured. The meta-analysis measured pain and stiffness, which are symptoms, and it did not measure inflammatory biomarkers or structural progression (Bakó et al., 2023). The largest effect occurred immediately after application, and one plausible interpretation, which the trials themselves do not establish, is that part of that early effect reflects sensory mechanisms rather than resolution of inflammation. Individual trials add to the picture without changing it, such as a randomized, double-blind trial that tested topical basil oil against an active comparator in knee osteoarthritis (Askari et al., 2024), and an animal study in which peppermint and rosemary oils in a nanoemulsion showed anti-osteoarthritic effects across behavioral, biochemical, and histopathological measures (Mohammadifar et al., 2021). A broader review of essential oils and bioactive components in arthritis likewise describes anti-inflammatory and analgesic potential while identifying the need for clinical confirmation (Marrelli et al., 2020).
Five specific limitations explain why these preclinical studies or molecular evidence cannot be trusted as clinical evidence for aromatherapy in inflammation:
Applying these limits, the table below rates the evidence of condition by condition. The ratings are an appraisal based on the sources cited in this article.
Types of Inflammation |
Best available evidence on inflammation |
Evidence level |
Realistic rolein inflammation |
Musculoskeletal pain and stiffness (a type of inflammation) |
Meta-analysis of eight trials (Bakó et al., 2023); basil oil trial in knee osteoarthritis (Askari et al., 2024) |
Human trials, small, with borderline significance beyond the first application |
Add-on symptom relief |
Gut inflammation |
Colon inflammation models with 1,8-cineole (Venkataraman et al., 2023) |
Preclinical |
No established clinical role |
Cardiovascular inflammation |
Mechanistic review of essential oils in atherosclerosis (Dabravolski et al., 2023) |
Mechanistic |
Not an established therapy |
Topical skin inflammation |
Bergamot nanocarrier study (Cristiano et al., 2022) |
Preclinical formulation study |
Dependent on delivery, not established for unformulated oils |
The literature analysis on the effect of aromatherapy in inflammation reflects a pattern that clearly states, in the case of chronic inflammation related to musculoskeletal pain, it is the only area with human trial evidence, and even there the evidence supports symptom relief as an add-on, not treatment of the underlying inflammation. This is the honest answer to the question of whether aromatherapy reduces inflammation: it probably reduces some symptoms or triggers of inflammation in the musculoskeletal setting, and its effect on inflammation itself in humans remains unproven.
Essential oils for autoimmune problems or chronic inflammation remain a clear gap in the evidence. Rheumatoid arthritis is a chronic autoimmune disease with defined pathological mechanisms of inflammation that are managed with modern pharmacologic therapies (Guo et al., 2018), and no evidence cited here suggests that an essential oil can replace disease-modifying antirheumatic drugs or biologic therapy. Some of the trials in the meta-analysis included patients with rheumatoid arthritis, but they measured pain and stiffness and not disease progression (Bakó et al., 2023). Similarly, once chronic inflammation has caused structural damage such as eroded cartilage or scarred tissue, the anti-inflammatory mechanisms described above address ongoing signaling and not the repair of existing injury. Anyone with a diagnosed autoimmune or structural inflammatory condition should therefore treat aromatherapy as a complementary layer and never as a replacement for medical treatment.
The practical use of aromatherapy for chronic inflammation is directed as follows:
Chronic inflammation is a measurable and consequential biological process, and the relationship between aromatherapy and chronic inflammation is better supported at the molecular level than most casual content suggests, but it is also more limited at the clinical level than marketing implies. The mechanisms are consistent across studies; it includes processes of inflammation, converging on NF-κB, MAPK, and oxidative stress. The human evidence is limited to symptom relief in musculoskeletal conditions, with effect sizes that are modest and, at some time points, statistically borderline.
Askari, A., Hasheminasab, F. S., Sadeghpour, O., Naghizadeh, M. M., Ravansalar, S. A., Iraji, A., & Hashempur, M. H. (2024). A randomized double-blind active-controlled clinical trial on the efficacy of topical basil (Ocimum basilicum) oil in knee osteoarthritis. Frontiers in Pharmacology, 15, 1377527. https://doi.org/10.3389/fphar.2024.1377527
Bakó, E., Fehérvári, P., Garami, A., Dembrovszky, F., Gunther, E. E., Hegyi, P., Csupor, D., & Böszörményi, A. (2023). Efficacy of topical essential oils in musculoskeletal disorders: Systematic review and meta-analysis of randomized controlled trials. Pharmaceuticals, 16(2), 144. https://doi.org/10.3390/ph16020144
Cristiano, M. C., d'Avanzo, N., Mancuso, A., Tarsitano, M., Barone, A., Torella, D., Paolino, D., & Fresta, M. (2022). Ammonium glycyrrhizinate and bergamot essential oil co-loaded ultradeformable nanocarriers: An effective natural nanomedicine for in vivo anti-inflammatory topical therapies. Biomedicines, 10(5), 1039. https://doi.org/10.3390/biomedicines10051039
Dabravolski, S. A., Sukhorukov, V. N., Melnichenko, A. A., Khotina, V. A., & Orekhov, A. N. (2023). Potential application of the plant-derived essential oils for atherosclerosis treatment: Molecular mechanisms and therapeutic potential. Molecules, 28(15), 5673. https://doi.org/10.3390/molecules28155673
de Lavor, É. M., Fernandes, A. W. C., de Andrade Teles, R. B., Leal, A. E. B. P., de Oliveira Júnior, R. G., Gama e Silva, M., de Oliveira, A. P., Silva, J. C., de Moura Fontes Araújo, M. T., Coutinho, H. D. M., de Menezes, I. R. A., Picot, L., & da Silva Almeida, J. R. G. (2018). Essential oils and their major compounds in the treatment of chronic inflammation: A review of antioxidant potential in preclinical studies and molecular mechanisms. Oxidative Medicine and Cellular Longevity, 2018, 6468593. https://doi.org/10.1155/2018/6468593
Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018). Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Research, 6(1), 15. https://doi.org/10.1038/s41413-018-0016-9
Ho, C.-L., Li, L.-H., Weng, Y.-C., Hua, K.-F., & Ju, T.-C. (2020). Eucalyptus essential oils inhibit the lipopolysaccharide-induced inflammatory response in RAW264.7 macrophages through reducing MAPK and NF-κB pathways. BMC Complementary Medicine and Therapies, 20, Article 200. https://doi.org/10.1186/s12906-020-02999-0
Li, X., Tong, M., Cao, H., Sun, X., & Zhang, F. (2025). Advances in essential oils for metabolic diseases. Frontiers in Endocrinology, 16, 1684179. https://doi.org/10.3389/fendo.2025.1684179
Marrelli, M., Amodeo, V., Perri, M. R., Conforti, F., & Statti, G. (2020). Essential oils and bioactive components against arthritis: A novel perspective on their therapeutic potential. Plants, 9(10), 1252. https://doi.org/10.3390/plants9101252
Mohammadifar, M., Aarabi, M. H., Aghighi, F., Kazemi, M., Vakili, Z., Memarzadeh, M. R., & Talaei, S. A. (2021). Anti-osteoarthritis potential of peppermint and rosemary essential oils in a nanoemulsion form: behavioral, biochemical, and histopathological evidence. BMC complementary medicine and therapies, 21(1), 57. https://doi.org/10.1186/s12906-021-03236-y
Nakadate, K., Ito, N., Kawakami, K., & Yamazaki, N. (2025). Anti-inflammatory actions of plant-derived compounds and prevention of chronic diseases: From molecular mechanisms to applications. International Journal of Molecular Sciences, 26(11), 5206. https://doi.org/10.3390/ijms26115206
Satoh, T., Trudler, D., Oh, C.-K., & Lipton, S. A. (2022). Potential therapeutic use of the rosemary diterpene carnosic acid for Alzheimer's disease, Parkinson's disease, and long-COVID through NRF2 activation to counteract the NLRP3 inflammasome. Antioxidants, 11(1), 124. https://doi.org/10.3390/antiox11010124
Venkataraman, B., Almarzooqi, S., Raj, V., Bhongade, B. A., Patil, R. B., Subramanian, V. S., Attoub, S., Rizvi, T. A., Adrian, T. E., & Subramanya, S. B. (2023). Molecular docking identifies 1,8-cineole (eucalyptol) as a novel PPARγ agonist that alleviates colon inflammation. International Journal of Molecular Sciences, 24(7), 6160. https://doi.org/10.3390/ijms24076160
No. The mechanistic evidence comes from cell and animal studies (de Lavor et al., 2018), and the human trials show symptom relief as an add-on treatment and not disease modification (Bakó et al., 2023).
Probably in the sense of reducing pain in some musculoskeletal conditions, because trials found a significant pain reduction immediately after application (p = 0.014) and at four weeks (p = 0.049) (Bakó et al., 2023). Whether it reduces inflammation itself is unproven, because those trials did not measure inflammatory biomarkers.
Carvacrol, thymol, terpinen-4-ol, and 1,8-cineole have the most identified mechanisms in the sources reviewed here (de Lavor et al., 2018; Venkataraman et al., 2023). They stand out because their activity has been tied to a specific compound and pathway, which is stronger than a claim about a plant name.
No. Autoimmune conditions such as rheumatoid arthritis are controlled with disease-modifying drugs and biologics (Guo et al., 2018), and no evidence cited here shows that an essential oil can substitute for them.
In cell and animal models, they inhibit NF-κB and MAPK signaling, reduce COX-2 and iNOS expression, and lower reactive oxygen and nitrogen species (de Lavor et al., 2018). These are the same processes that sustain chronic inflammatory damage, but the findings come from preclinical models.